A clinical study evaluating the pharmacokinetic of Biosimilar Injection Tenecteplase (Hetero Biopharma Limited) compared to Tenecteplase ( Boehringer Ingelheim) in adult Patients of Myocardial Infarction
Latest Information Update: 03 Nov 2023
At a glance
- Drugs Tenecteplase (Primary)
- Indications Myocardial infarction
- Focus Pharmacokinetics
Most Recent Events
- 03 Nov 2023 New trial record
- 12 Sep 2023 Results presented at the 2023 American College of Clinical Pharmacology Annual Meeting